Is J147 an acetylcholinesterase inhibitor?

No. J147 is neither an acetylcholinesterase inhibitor nor a phosphodiesterase inhibitor, which is what distinguishes it mechanistically from the symptomatic Alzheimer's drugs it is often compared with.

Does J147 target amyloid?

No. J147 was never designed against amyloid. It was selected in cell-based phenotypic screens built around old-age-associated brain toxicities, and its identified target is a mitochondrial enzyme, not a plaque.

Mechanism · ATP5A · Aging Cell, 2018

The target was found seven years after the molecule

J147 binds the alpha subunit of mitochondrial F1-ATP synthase — the protein ATP5A. Modulating ATP synthase changes intracellular calcium handling and engages CAMKK2 and AMPK stress-resilience signalling, producing more stable mitochondria in ageing and disease models. The paper reporting it calls ATP synthase a shared drug target for aging and dementia — in its title.

J147 is neither an acetylcholinesterase inhibitor nor a phosphodiesterase inhibitor. It was never aimed at amyloid. Its target was not designed for; it was discovered, and the order of events is the most informative thing about it.

The order of discovery

2011 — the moleculeA medicinal-chemistry programme at the Salk Institute builds curcumin derivatives and screens them in cell assays modelled on old-age-associated brain toxicities. J147 emerges with neurotrophic activity curcumin does not have. Nobody knows what it binds.

2013 — the effectJ147 reverses cognitive impairment in aged APP/PS1 mice, given late in the disease rather than prophylactically, and the pharmacokinetics are measured. Still nobody knows what it binds.

2018 — the targetGoldberg, Currais, Prior, Schubert, Maher and colleagues identify ATP5A, the alpha subunit of mitochondrial F1-ATP synthase, and show that manipulating ATP synthase activity reproduces the protection. Aging Cell 17:e12715.

2019–2020 — the human studyAbrexa runs a Phase 1 of single ascending oral doses in 64 healthy young and elderly volunteers. It completes. No results are posted.

A phenotypic screen does not tell you what your compound hits. That is usually described as its weakness. Here it was the strength: had the programme started from a target hypothesis, the target it found is not one anybody would have proposed.

The chain as reported: binding at ATP5A, a shift in calcium handling, CAMKK2, AMPK, and stress resilience downstream. The rotor turns continuously because the enzyme is not switched off — J147 modulates it. Original diagram, Panacea Bio Chem.

Why one target can serve both ageing and dementia

The conventional arrangement is one disease, one drug: something for Alzheimer's, something else for Parkinson's, something else again for stroke. The Salk position is that these share an upstream driver — the ageing of the brain itself — and that a compound selected against ageing toxicities rather than against a single pathology can act upstream of all of them.

ATP synthase is a plausible place for that to be true. It sits at the end of oxidative phosphorylation, it is central to the cell's energy budget, and its decline is a general feature of ageing tissue rather than a feature of one disease.

What it is not

Not an acetylcholinesterase inhibitor. Not a phosphodiesterase inhibitor. Not an anti-amyloid agent. Not approved anywhere, for anything.

What has been shown

Cognitive rescue in aged transgenic mice given the compound late in disease; preservation of synaptic proteins across ageing and neurodegeneration models; lifespan extension in flies; effects on plasma fatty acids via AMPK/ACC1 in liver.

Next: every claim, with its source The reference table — primary source, model, dose and year for each row, including the Chinese literature and the Russian null result. Or: why the mechanism needs a dosage form A 1.5-hour plasma half-life makes exposure a design problem, not an afterthought.